Correspondence 0001193125-22-285729 from Achilles Therapeutics plc (ACHL) (CIK 0001830749)
Achilles Therapeutics plc (ACHL) (CIK 0001830749)
Date: Nov. 15, 2022 · CIK: 0001830749 · Accession: 0001193125-22-285729
AI Filing Summary & Sentiment
File numbers found in text: 333-268239
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Attention: Jimmy McNamara Re: Achilles Therapeutics plc Acceleration Request for Registration Statement on Form F-3 File No. 333-268239
Dear Jimmy McNamara,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Achilles Therapeutics plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 17, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Meg Dennard at (212) 813-8927.
If you have any questions regarding this request, please contact Seo Salimi of Goodwin Procter LLP at (212) 459-7234 or Meg Dennard at (212) 813-8927.
Sincerely,
ACHILLES THERAPEUTICS PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR November 15, 2022 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jimmy McNamara Re: Achilles Therapeutics plc Acceleration Request for Registration Statement on Form F-3 File No. 333-268239 Dear Jimmy McNamara, Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Achilles Therapeutics plc (the “Company”) hereby requests that the effective date of the above-referenced registration statement (the “Registration Statement”) be accelerated to November 17, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP by calling Meg Dennard at (212) 813-8927. If you have any questions regarding this request, please contact Seo Salimi of Goodwin Procter LLP at (212) 459-7234 or Meg Dennard at (212) 813-8927. Sincerely, ACHILLES THERAPEUTICS PLC /s/ Iraj Ali Iraj Ali Chief Executive Officer cc: Iraj Ali, Achilles Therapeutics plc Daniel C. C. Hood, Achilles Therapeutics plc Seo Salimi, Esq., Goodwin Procter LLP Meg Dennard, Esq., Goodwin Procter LLP